What are the side effects of ruxolitinib tablets/ruxolitinib?

Ruxolitinib is a kinase inhibitor available in tablet form containing 5, 10, 15 or 20 mg of ruxolitinib. After marketingfor the treatment of myelofibrosis (MF) in adults with splenomegaly (enlargement of the spleen) or symptoms associated with this disease, including primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis; orPolycythemia vera (PV) in adults with resistance or intolerance to hydroxyurea; or steroid-refractory acute graft-versus-host disease (GVHD) in adults and pediatric patients 12 years of age and older and chronic GVHD after failure of one or two systemic therapies.

In myelofibrosis, the most common side effects of ruxolitinib include thrombocytopenia (low platelet count), anemia (low red blood cell count), neutropenia (low neutrophil levels), bleeding, bruising, hypertriglyceridemia (high blood lipid levels), dizziness, and increased liver enzyme levels. In polycythemia vera, the most common side effects of ruxolitinib include thrombocytopenia, anemia, weight gain, headache, dizziness, hypercholesterolemia (high blood cholesterol levels), and increased liver enzyme levels.

In acute graft-versus-host disease, the most common side effects of ruxolitinib include thrombocytopenia, anemia, neutropenia, cytomegalovirus infection, sepsis (organ damage caused by bacteria and their toxins circulating in the blood), urinary tract (structure that carries urine) infection, hypercholesterolemia, and elevated liver enzyme levels. The most common side effects of ruxolitinib in chronic graft-versus-host disease include thrombocytopenia, anemia, neutropenia, hypertension, headache, urinary tract infection, hypercholesterolemia, and elevated liver enzyme levels.